Resupply of Paxil CR

GlaxoSmithKline PLC 27 June 2005 GlaxoSmithKline Announces Resupply of Paxil CR to US Market London and Philadelphia (27 June 2005) - GlaxoSmithKline (GSK) announced today the availability of Paxil CR (paroxetine hydrochloride controlled release) tablets in pharmacies across the United States. Other markets will follow shortly thereafter. GSK committed to resupplying pharmacies and wholesalers by mid-year after disruption of supply following the company's voluntary withdrawal of the product in February due to manufacturing issues. Both the company and the US Food and Drug Administration (FDA) agreed at the time that the manufacturing issues posed no significant safety issues for patients. GSK has identified the source of the manufacturing issues and has implemented revisions to those processes, as certified by a third party. Paxil CR is approved for the treatment of major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric disorder. With respect to Avandamet (rosiglitazone maleate/metformin hydrochloride) tablets, the Company anticipates resupplying the distribution channels within two weeks. S M Bicknell Company Secretary 27 June 2005 GlaxoSmithKline - one of the world's leading research-based pharmaceutical and health care companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Enquiries: UK Media enquiries: Philip Thomson (020) 8047 5502 David Mawdsley (020) 8047 5502 Chris Hunter-Ward (020) 8047 5502 Alice Hunt (020) 8047 5502 US Media enquiries: Nancy Pekarek (215) 751 7709 Mary Anne Rhyne (919) 483 2839 Patricia Seif (215) 751 7709 European Analyst/Investor enquiries: Duncan Learmouth (020) 8047 5540 Anita Kidgell (020) 8047 5542 Jen Hill (020) 8047 5543 US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002 Tom Curry (215) 751 5419 This information is provided by RNS The company news service from the London Stock Exchange

Companies

GSK (GSK)
UK 100